Phase 2 results of ZP-PTH for osteoporosis

Zosano Pharma announced that an abstract detailing results of its Phase 2 study of ZP-PTH for the treatment of established osteoporosis will be presented as a poster at the 8th International Symposium on Osteoporosis in Washington D.C.  

ZP-PTH, a transdermal patch formulation of parathyroid hormone (PTH), is being developed as an alternative to daily injections.

For more information call (510) 745-1200 or visit